TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback